David Scott Jones - 28 Feb 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
28 Feb 2022
Net transactions value
-$11,244
Form type
4
Filing time
02 Mar 2022, 17:22:00 UTC
Previous filing
11 Feb 2022
Next filing
10 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4,105 +33% $0.000000 16,729 28 Feb 2022 Direct
transaction EYPT Common Stock Tax liability $11,244 -1,130 -6.8% $9.95 15,599 28 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -4,105 -100% $0.000000* 0 28 Feb 2022 Common Stock 4,105 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2 The restricted stock units vested in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.